Psoriasis | Janssen | CNTO1959PSO3011
Pharmaceutical Company/Sponsor:
Janssen
Code:
CNTO1959PSO3011
Title:
A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (>=6 To <18 Years of Age)
Type:
Interventional
Phase:
3
Condition/Disease:
Psoriasis
Intervention(s)/Treatment(s):
Drug: Guselkumab
Drug: Placebo for Guselkumab
Drug: Etanercept
Status:
Recruiting
Link for Additional Information:
